Published in N Z Med J on November 25, 2011
Response to PHARMAC on Access to new medicines in New Zealand compared to Australia. N Z Med J (2011) 0.76
Identifying priority medicines policy issues for New Zealand: a general inductive study. BMJ Open (2014) 0.75
Access to new medicines in New Zealand compared to Australia. N Z Med J (2011) 1.98
PHARMAC responds on long-acting insulin analogues. N Z Med J (2005) 1.53
Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. N Z Med J (2005) 1.53
Variation in the use of medicines by ethnicity during 2006/07 in New Zealand: a preliminary analysis. N Z Med J (2013) 1.40
PHARMAC and tobacco control in New Zealand: two licensed funded options are already available. N Z Med J (2005) 1.40
PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly. N Z Med J (2005) 1.39
Terminations of pregnancy associated with isotretinoin use in New Zealand. N Z Med J (2011) 1.39
Climate science, denial and the Declaration of Delhi. N Z Med J (2009) 1.39
Direct-to-consumer advertising--yes it can compromise patient health. N Z Med J (2003) 1.39
PHARMAC responds to Richard Milne on discounting health benefits and costs. N Z Med J (2005) 1.36
Health and equity impacts of climate change in Aotearoa-New Zealand, and health gains from climate action. N Z Med J (2014) 0.99
PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists. N Z Med J (2005) 0.97
Our advice? Get a budget! Healthc Pap (2002) 0.94
Old letters, new rules. Lancet (2003) 0.93
National prescribing data for dabigatran. N Z Med J (2012) 0.85
Response from PHARMAC: difficult choices. N Z Med J (2003) 0.84
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated. BMJ (2003) 0.81
Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis. N Z Med J (2013) 0.80
Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices. J Allergy Clin Immunol (2004) 0.79
PHARMAC responds on Herceptin assumptions and decisions. N Z Med J (2007) 0.78
PHARMAC responds on salbutamol. N Z Med J (2005) 0.76
PHARMAC responds on long-acting inhalers for COPD. N Z Med J (2005) 0.76
PHARMAC and EpiPen for anaphylaxis. N Z Med J (2006) 0.75
PHARMAC and statins--correction is needed. N Z Med J (2007) 0.75
PHARMAC and erythropoietin for cancer patients. N Z Med J (2006) 0.75
PHARMAC's response on gemcitabine and transparency. N Z Med J (2005) 0.75
PHARMAC and statins--getting the best population health gains. N Z Med J (2006) 0.75
Funding a clinical trial: the perspective of a medicines funder. Pharmacoeconomics (2008) 0.75
More on PHARMAC and tobacco control in New Zealand. N Z Med J (2006) 0.75
PHARMAC responds on agents to prevent osteoporotic fractures. N Z Med J (2006) 0.75
PHARMAC responds on treatments for pulmonary arterial hypertension. N Z Med J (2005) 0.75
PHARMAC responds on TNF inhibitors for inflammatory arthritis. N Z Med J (2005) 0.75
Balancing the risks and benefits of celecoxib. Am J Med (2007) 0.75
Child abuse in Australian camps-whose business, and who should speak out? N Z Med J (2016) 0.75
PHARMAC has no cost-effectiveness threshold. N Z Med J (2012) 0.75
New Zealand's emissions trading scheme and health: wasting our opportunities. N Z Med J (2008) 0.75
Usage and equity of access to isotretinoin in New Zealand by deprivation and ethnicity. N Z Med J (2011) 0.75
PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metric. N Z Med J (2012) 0.75
PHARMAC's updated guidelines for cost-effectiveness analyses, with new discount rate. N Z Med J (2007) 0.75
Sign On--prescribing for climate health. N Z Med J (2009) 0.75
Specific oral contraceptive use and venous thromboembolism resulting in hospital admission. N Z Med J (2004) 0.75
PHARMAC welcomes debate. N Z Med J (2005) 0.75